Items where authors include "Oughton, J.B."

Article

Walker, K. orcid.org/0000-0001-6922-9100, Hinsley, S., Phillip, R. orcid.org/0000-0002-9604-9276 et al. (6 more authors) (2022) Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology, 6 (6). e2200133. ISSN 2473-4284

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Oughton, J.B. orcid.org/0000-0002-2047-804X, Poad, H., Twiddy, M. et al. (14 more authors) (2017) Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ Open, 7 (8). e017913.

Conference or Workshop Item

Hussain, S.A., Oughton, J.B. orcid.org/0000-0002-2047-804X, Smith Whelan, R. et al. (11 more authors) (2025) A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts. In: 2025 ASCO Genitourinary Cancers Symposium, 13-15 Feb 2025, San Francisco, CA.

Hussain, S.A., Oughton, J.B. orcid.org/0000-0002-2047-804X, Smith Whelan, R. et al. (9 more authors) (2024) INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. In: 2024 ASCO Genitourinary Cancers Symposium, 25-27 Jan 2024, San Francisco, CA.

Proceedings Paper

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Crabb, S.J., Hussain, S.A., Oughton, J.B. et al. (15 more authors) (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. American Society of Clinical Oncology .

Horne, A., Brown, S., Gilbert, A. et al. (16 more authors) (2024) Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm. In: Radiotherapy and Oncology. ESTRO 2024, 03-07 May 2024, Glasgow, UK. , S1652-S1655.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.